Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

KP-496

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Cysteinyl-leukotrienes (cysLTs) and thromboxane A(2) (TXA(2)) are important mediators in inflammatory lung diseases such as… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2009
2009
Bronchial asthma is characterized by chronic airway inflammation. Eosinophils are involved in airway inflammation and play… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
2009
2009
Aims: The aim of this study was to evaluate the effects of inhaled KP-496, a novel dual antagonist for cysteinyl leukotriene… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
BACKGROUND AND PURPOSE KP-496 is a novel dual antagonist for cysteinyl leukotriene receptor 1 (CysLT(1)) and thromboxane A(2… Expand
Is this relevant?
2007
2007
Abstract.Objective and design:KP-496 is a novel dual antagonist for leukotriene (LT) D4 and thromboxane (TX) A2 receptors. We… Expand
  • figure 1
  • figure 2
  • table 1
  • table 3
  • table 2
Is this relevant?
2006
2006
BACKGROUND A dry powder inhaler of KP-496 is currently in clinical development in Japan as an anti-asthmatic agent. The aim of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?